Tumor biology has become a significant factor for the management of gastric cancer and its treatment. It is known that all gastric cancers are not alike and can be classified into different subtypes. Recently, increasing attention has been focused on human epidermal growth factor receptor 2 (HER2), which is expressed at higher levels in some gastric cancers.
Having identified whether or not a tumor is HER2-positive, HER2-positive tumors may have biological characteristics that differ from other gastric cancers and is being treated with distinct strategies, often in conjunction with other approaches, such as chemotherapy and radiation, and currently also with the emerging class of cancer drugs, known as immunotherapies.
Table of Contents
Understanding HER2-Positive Gastric Cancer
HER2 is a receptor on cancer cells for human epidermal growth factor. The signaling from the HER2 receptor promotes cancer cell growth, survival and angiogenesis (the formation of new blood vessels which supply the tumor with nutrients and enable the tumor to grow). In some gastric cancers, the amount of the HER2 protein on the surface of cancer cells or the number of copies of the HER2 gene that the cancer cells contain is higher than usual. By testing HER2, gastric cancers can be identified as being HER2 positive (see HER2 Testing section below).
Importantly, knowing a tumor is HER2-positive allows the oncologist to consider the tumor’s molecular profile when choosing a treatment; in other words, the tumor is not just being treated as a stomach cancer. However, the decision on whether to use a HER2-targeted therapy is based on other factors such as the cancer stage and location, previous treatment(s), patient’s general health, presence of other biomarkers and individual patient circumstances.
Advances in HER2 Testing
For precise testing for HER2-expressing tumors, samples from tumor tissue, obtained by a biopsy or a surgery, are analyzed. Laboratory analysis measures the amount of HER2 protein produced by cancer cells and amplification of the HER2 gene.
Methods of laboratory are commonly used to determine the amount of HER2 proteins in gastric cancer cells and to analyze the HER2 gene in these cells for amplification and other alterations. The results from such tests are then interpreted according to established criteria.
An additional challenge with gastric cancer is that they are often heterogeneous so that different parts of the same tumor can have different biological characteristics and can express different levels of HER2. There is considerable interest in methods to better understand individual tumors.
Targeted Therapy and Changing Treatment Strategies
Targeted therapy is one of several treatment approaches used in oncology. These therapies are designed to target specific molecular pathways involved in cancer growth.
HER2-directed therapies are those that target part of the tumor cell with the altered HER2 receptor. Such therapies are designed to target HER2-related signaling pathways. Each of the HER2-directed treatments have different mechanisms of action. Some are bonded to HER2 proteins on cancer cells and others deliver therapeutic components into cells that express HER2. The availability of certain treatments and the recommendation of these in relation to other options is dependent upon current clinical practice.
Combining Different Cancer Treatments
For the main types of gastric cancer, apart from the above-mentioned treatments, also other methods such as chemotherapy, surgery, immunotherapy or radiation therapy can be applied to the individual case. Often a combination of several methods is used.
Combination therapies utilize different treatment mechanisms that may complement one another. Therefore, chemotherapy, for example, acts differently than a HER2-directed treatment. The potential of treatments being combined must be weighed against the possible side effects for the patient. But again, more drugs can also have more side effects. Therefore, must carefully weigh up the potential benefits against the possible risks for each individual patient.
The Expanding Role of Immunotherapy
Immunotherapies also are under investigation to treat gastric cancer, to make the patient’s immune system recognize and attack cancer cells.
This assessment can require the evaluation of other tumor biomarkers as well as several clinical characteristics. Given that HER2 status by itself is not enough to determine suitability for immunotherapy, several other parameters must be assessed. There is interest in evaluating how immunotherapy approaches may be used in combination with HER2 targeted approaches to treat cancers that express excess HER2 proteins. Further investigation is needed into how these two strategies interact to affect cancer cells.
Addressing Treatment Resistance
One major problem in treating cancer is tumor resistance. A tumor or cancer may initially respond to a certain treatment but soon may return to grow. There are also cases where cancer only poorly responds to treatment from the very beginning.
Resistance to treatment can be developed by cancer cells as they go through changes in their biology which allow them to avoid the targeted action of a treatment. Cancer tumors are also very heterogeneous, and it may be that some cancer cells within a tumor have lower sensitivity to a particular treatment. Working to better understand cancer resistance to treatments can also lead to the development of different treatments including novel drug combinations, alternate targets, and even different treatment sequences to better address cancer progression.
Biomarkers and More Individualized Care
Additional tumor characteristics may help guide treatment for individual patients with gastric cancer. In addition to HER2 status, for example, other biomarkers could influence therapy choices. Increasing availability of molecular diagnostics allows for analysis of additional biomarkers to guide therapy of gastric cancer. This approach supports precision medicine by incorporating tumor characteristics into treatment planning.
Monitoring Treatment Response
On treatment, patients with cancer need to have regular check-ups to see if the cancer is shrinking or not. This can be done by measuring symptoms or by using Imaging studies, laboratory tests, physical examination or by assessing symptoms.
Monitoring for side effects and treatment response: The side effects of cancer treatment can vary widely depending on the specific therapy used and even how a particular treatment is combined with other cancer therapies. In some cases, severe complications can require a change in treatment or even require treatment by another medical physician. It is important for patients to inform their healthcare team immediately if they develop any new symptoms or if their current symptoms become worse, even if it is outside of their appointment times.
Looking Toward the Future
Innovations in treatment for patients with HER2 positive gastric cancer are continually evolving through tumor testing, targeted and immunotherapy treatments, as well as further research on biomarkers and cancer resistance. Many more HER2-directed treatments and ways to select patients for specific treatments are under investigation for the treatment of gastric cancer at all stages.
For patients and families looking for information regarding her2 positive stomach cancer treatment it will help with looking up current information regarding the cancer and how it is being treated and to be better prepared for discussions with oncologists regarding the best treatment options for individual cases. As knowledge of HER2 positive gastric cancer continues to evolve, it may contribute to ongoing developments in cancer treatment approaches from a location-based to a biology-based approach.
Disclaimer: The information provided in this article is intended for educational purposes only and should not be interpreted as medical advice, a clinical guideline, or a recommendation for any specific treatment.
